

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Guidance development**

**STA: Sotorasib for previously treated KRAS G12C mutated,  
locally advanced or metastatic non-small-cell lung cancer  
[ID3780]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

British Thoracic Oncology Group highlighted that KRAS mutation is less common in lung cancer from East and South Asian populations, but nevertheless relevant in all NSCLC populations

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Differences in incidence of a disease cannot be addressed in a technology appraisal. Stakeholders can submit evidence on differing diagnosis timeliness, outcomes and quality of life between different populations.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

N/A

4. Have any additional stakeholders related to potential equality issues

Technology Appraisals: Guidance development

Equality impact assessment for the Single Technology Appraisal of sotorasib for previously treated KRAS G12C mutated, locally advanced or metastatic non-small-cell lung cancer [ID3780]

Issue date:

been identified during the scoping process, and, if so, have changes to the matrix been made?

No

**Approved by Associate Director (name):** Jasdeep Hayre

**Date:** 23 April 2021

## **Final appraisal determination**

(when no ACD was issued)

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

Issues related to differences in prevalence or incidence of a disease cannot be addressed in a technology appraisal.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

No equality issues have been raised in the submissions.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No equality issues have been raised by the committee.

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the

specific group?
No.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
N/A

7. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?
No equality issues were identified (section 3.16 of the FAD)

**Approved by Associate Director (name):** Jasdeep Hayre

**Date:** 22 Feb 2022